Peer Review History

Original SubmissionAugust 21, 2022
Decision Letter - Alessandra Coin, Editor

PONE-D-22-23424Development of a Simple Screening Tool for Determining Cognitive Status in Alzheimer’ DiseasePLOS ONE

Dear Dr. Chiu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Dec 10 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Alessandra Coin

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

O agree with both reviewers for a minor revision of the manuscript and I think they raised interesting points to imporve the quality of yoou manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Authors propose an interesting and easy-to-administer tool for the detection of cognitive impairment and, even more interestingly, for differentiating between MCI and dementia. I certainly encourage this paper to be published because of its likely utility in daily clinical practice.

I only have one minor comment that I would like the authors may discuss. Although they mentioned educational level and, as a matter of fact, they did not find an association with the pathology evolution, in such a study, I would expect some considerations about cognitive reserve and its role in modulating not only the onset, but also the progression of cognitive impairment.

Furthermore, although MMSE has important limitations (clinical, first of all!), it would be helpful also a comparison/a critical consideration or comment referring HAI-SAC to MMSE which is, at the date, the most applied screening test for dementia (authors certainly know that MoCA is more difficult and more focused on executive functions rather than MMSE which is easier and, for some aspects, more suitable for older individuals).

Reviewer #2: Dear Editor, Thank you for your invitation.

ABSTRACT should be re-written in order to provide clearer information to the readers.

Please provide the mean age and female percentage of the study population. How many patients were diagnosed with MCI, AD and control group? What was the sensitivity, specifity of the HAI-SAC to detect MCI and AD? And it would be better ig the authors mention the AUC results about discriminating MCI from NC/AD.

INTRO: The authors should give some examples about short screening tools (https://pubmed.ncbi.nlm.nih.gov/28660847/, https://pubmed.ncbi.nlm.nih.gov/29923472/)

RESULTS is well-written, but is there any information about comorbidities of the patients?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Maria Deita

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

PLOS ONE

Referee Report on the Revised Version of Manuscript PONE-D-22-23424

“Development of a Simple Screening Tool for Determining Cognitive Status in Alzheimer’s Disease”

We are grateful for your invaluable assistance in the revision of this paper. We have closely followed the guidance provided by the reviewers and editors in this revision. Detailed responses to the comments are provided below.

Journal Requirements

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Reply:

The formatting of the revised manuscript has been adjusted in accordance with journal requirements.

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information. If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information. Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”). For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

Reply:

As the data were analyzed retrospectively and anonymously from a database established in previous Taiwanese studies, informed consent was waived. We have provided the information in the Methods section of the revised manuscript (Lines 12 to 15, Page 7).

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Reply:

We have uploaded a de-identifying minimum dataset that can support the conclusions of the manuscript on BioStudies Submission Tool (accession number: S-BSST951). We have added a section (Data Availability) in the revised manuscript (Lines 14 to 15, Page 24).

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Reply:

We have corrected and updated the reference list in the revised manuscript (Page 25 to 35).

5. Additional Editor Comments: I agree with both reviewers for a minor revision of the manuscript and I think they raised interesting points to improve the quality of your manuscript.

Reply:

We have closely followed the guidance provided by the reviewers in this revision.

Reviewer 1

Authors propose an interesting and easy-to-administer tool for the detection of cognitive impairment and, even more interestingly, for differentiating between MCI and dementia. I certainly encourage this paper to be published because of its likely utility in daily clinical practice.

1. I only have one minor comment that I would like the authors may discuss. Although they mentioned educational level and, as a matter of fact, they did not find an association with the pathology evolution, in such a study, I would expect some considerations about cognitive reserve and its role in modulating not only the onset, but also the progression of cognitive impairment.

Reply:

We have addressed the issue of cognitive reserve in the Discussion section of the revised manuscript (Lines 10 to 14, Page 14 and Line 20, Page 21 to Line 1, Page 22).

2. Furthermore, although MMSE has important limitations (clinical, first of all!), it would be helpful also a comparison/a critical consideration or comment referring HAI-SAC to MMSE which is, at the date, the most applied screening test for dementia (authors certainly know that MoCA is more difficult and more focused on executive functions rather than MMSE which is easier and, for some aspects, more suitable for older individuals).

Reply:

We have added a comparison and addressed the sensitivity and specificity of HAI-SAC and MMSE in the Discussion section of the revised manuscript (Lines 11 to 18, Page 22). We have also mentioned the limitation imposed by our use of an extracted MMSE score (Lines 21 to 23, Page 23).

Reviewer 2

1. ABSTRACT should be re-written in order to provide clearer information to the readers.

Reply:

We have re-written the Abstract in the revised manuscript (Page 3).

2. Please provide the mean age and female percentage of the study population.

Reply:

We have provided this information in the Results (Lines 12 to 14, Page 13) and Abstract (Lines 5 to 6, Page 3) section of the revised manuscript.

3. How many patients were diagnosed with MCI, AD and control group?

Reply:

A total of 397 participants were diagnosed with AD dementia, 231 were diagnosed with MCI, and 136 were diagnosed as CU. This information has been included in the Methods section (Lines 10 to 12, Page 7) and Table 1 of the revised manuscript. We have also provided this information in the Abstract section of the revised manuscript (Lines 6 to 7, Page 3).

4. What was the sensitivity, specificity of the HAI-SAC to detect MCI and AD?

Reply:

In differentiating between MCI and NC, the sensitivity of HAI-SAC was 0.87 and the specificity was 0.58, with a cut-off score of 41/42. In differentiating between MCI and DAT, the sensitivity of HAI-SAC was 0.78 and the specificity was 0.84, with a cut-off score of 33/34. In differentiating between NC and DAT, the sensitivity of HAI-SAC was 0.99 and the specificity was 0.89, with a cut-off score of 35/36. This information has been included in the Results section of the revised manuscript (Lines 2 to 11, Page 16; Lines 7 to 14 and Lines 18 to 21, Page 17). We have also provided the information in the Abstract section of the revised manuscript (Line 19, Page 3 to Line 1, Page 4) and corrected typos in Table 4 (Page 19).

5. And it would be better if the authors mention the AUC results about discriminating MCI from NC/AD.

Reply:

This information has been included in the Results section and Table 4 of the revised manuscript (Pages 18 to 19). We have also included this information in the Abstract section of the revised manuscript (Line 22, Page 3 to Line 1, Page 4).

6. INTRO: The authors should give some examples about short screening tools (https://pubmed.ncbi.nlm.nih.gov/28660847/, https://pubmed.ncbi.nlm.nih.gov/29923472/)

Reply:

We have included an introduction to these tools in the Introduction section of the revised manuscript (Lines 13 to 15, Page 5).

7. RESULTS is well-written, but is there any information about comorbidities of the patients?

Reply:

We have listed the proportion of individuals with hypertension, diabetes, hypercholesterolemia, or coronary artery disease across groups in the Methods (Lines 6 to 8, Page 7) and Results (Lines 1 to 4, Page 14) sections and Table 1 of the revised manuscript (Page 14).

Attachments
Attachment
Submitted filename: Response to reviewer_1123.docx
Decision Letter - Alessandra Coin, Editor

Development of a Simple Screening Tool for Determining Cognitive Status in Alzheimer’s Disease

PONE-D-22-23424R1

Dear Dr. Chiu,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Alessandra Coin

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Maria Devita

Reviewer #2: Yes: Pinar Soysal

**********

Formally Accepted
Acceptance Letter - Alessandra Coin, Editor

PONE-D-22-23424R1

Development of a simple screening tool for determining cognitive status in Alzheimer’s disease

Dear Dr. Chiu:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Alessandra Coin

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .